Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages
Macrophages are dominant cells in the pathogenesis of atherosclerosis. They are also a major source of reactive oxygen species (ROS). Oxidative stress, which is particularly high in subjects with diabetes, is responsible for accelerated atherosclerosis. Novel antidiabetic drugs (e.g., glucagon-like...
Main Authors: | Bułdak, Łukasz, Łabuzek, Krzysztof, Bułdak, Rafał Jakub, Machnik, Grzegorz, Bołdys, Aleksandra, Okopień, Bogusław |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer Berlin Heidelberg
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537507/ |
Similar Items
-
The influence of ezetimibe on classical and alternative activation pathways of monocytes/macrophages isolated from patients with hypercholesterolemia
by: Suchy, Dariusz, et al.
Published: (2014) -
A Novel, Highly Selective RT-QPCR Method for Quantification of MSRV Using PNA Clamping Syncytin-1 (ERVWE1)
by: Machnik, Grzegorz, et al.
Published: (2015) -
The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
by: Andreozzi, Francesco, et al.
Published: (2016) -
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
by: Rosenstock, Julio, et al.
Published: (2013) -
Differential Protective Effects of Exenatide, an Agonist of GLP-1 Receptor and Piragliatin, a Glucokinase Activator in Beta Cell Response to Streptozotocin-Induced and Endoplasmic Reticulum Stresses
by: Kim, Mi-Kyung, et al.
Published: (2013)